3 unknown, 1 recruiting. 2 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 2 | Recruiting 1, Unknown 1 |
Follow Qing XIe: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pegylated Interferon α in Previously Interferon-treated CHB（Leading Study） Peginterferon α-2b based treatment group, NAs monotherapy group - Chronic Hepatitis b | Not applicable | Recruiting | Qing XIe | 2016 | 2024-02-04 | 2024-03-21 |
| Risk of Hepatocellular Carcinoma in Patients Treated With ETV vs TDF for Chronic Hepatitis B With Compensated Cirrhosis Entecavir, Tenofovir Disoproxil - Hepatitis B, Chronic, Hepatocellular Carcinoma | Unknown | Qing XIe | 4000 | 2019-10-22 | 2019-11-13 | |
| A Prospective Study to Evaluate Peginterferon in Reducing the Incidence of HCC in CHB Patients Peginterferon alfa-2b Injection, Nucleos (t) ide Analogue, Nucleos(t)ide analogue - Chronic Hepatitis B, Intermediate to High Risk of HCC | Not applicable | Unknown | Qing XIe | 267 | 2019-07-03 | 2023-05-25 |
| Effectiveness and Safety of Direct-Acting Antiviral Agents for the Treatment of Chronic Hepatitis C Direct-acting antiviral agents - Hepatitis C, Chronic | Unknown | Qing XIe | 300 | 2019-03-06 | 2021-07-07 |
Hepatitis B, Chronic (3) · Carcinoma, Hepatocellular (2) · Hepatitis C, Chronic (1)
Sofosbuvir (1) · Tenofovir (1) · asunaprevir (1) · daclatasvir (1) · danoprevir (1) · dasabuvir (1) · elbasvir (1) · entecavir (1) · glecaprevir (1) · grazoprevir (1) · ledipasvir (1) · ombitasvir (1) · paritaprevir (1) · peginterferon alfa-2b (1) · pibrentasvir (1)
China (4)